XTL Biopharmaceuticals
XTLB
5 hedge funds and large institutions have $728K invested in XTL Biopharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 1 closing their positions.
158% more capital invested
Capital invested by funds: $282K → $728K (+$446K)
0% more funds holding
Funds holding: 5 → 5 (0)
0% less ownership
Funds ownership: 0.01% → 0.01% (-0%)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$15.8K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$7.97K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$46.7K |
| 2 |
CTC
Central Trust Company
Jefferson City,
Missouri
|
-$203 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
NI
1
Noked Israel
Ramat Hasharon,
Israel
| $559K | – | – | – |
|
|
2
Morgan Stanley
New York
| $110K | -$46.7K | -10,093 | -51% |
|
|
3
Citadel Advisors
Miami,
Florida
| $38.3K | +$15.8K | +3,408 | New |
|
|
4
UBS Group
Zurich,
Switzerland
| $19.5K | +$7.97K | +1,725 | +12,321% |
|
5
BNP Paribas Financial Markets
Paris,
France
| $843 | – | – | – |
|
|
CTC
6
Central Trust Company
Jefferson City,
Missouri
| – | -$203 | -50 | Closed |
|
XTLB Hedge Fund Activity: Q1 2024 in Review
5 of the 6,947 institutional investors tracked by Wall St. Rank reported a position in XTL Biopharmaceuticals (XTLB) for Q1 2024, worth a combined $728K — up 158% from $282K a quarter earlier.
Fund positioning in XTLB was balanced in Q1 2024: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 1 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $15.8K. The largest seller was Morgan Stanley, cutting an estimated $46.7K.
- 5 institutional investors held XTL Biopharmaceuticals (XTLB) as of Q1 2024, unchanged from Q4 2023.
- Funds reported $728K of XTL Biopharmaceuticals stock for Q1 2024, up 158% quarter-over-quarter.
- 1 fund opened new XTL Biopharmaceuticals positions in Q1 2024 and 1 closed out, a net change of 0 holders.
- The largest XTL Biopharmaceuticals buyer in Q1 2024 was Citadel Advisors, an estimated $15.8K added.
- The largest XTL Biopharmaceuticals seller in Q1 2024 was Morgan Stanley, an estimated $46.7K sold.
Based on aggregated 13F filings for Q1 2024.